Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 5 · 71.4%High 0 · 0%

3‐year OS · patients with epithelial ovarian cancer

Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).

1 finding from 1 review

Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
RR 1.06 [0.85, 1.32]
1 study · 141 participants
Low

3‐year OS · patients with epithelial ovarian cancer

Maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).

1 finding from 1 review

Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
RR 1 [0.92, 1.08]
5 studies · 679 participants
Moderate

Progression‐free survival · patients with epithelial ovarian cancer

Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).

1 finding from 1 review

Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
RR 1.07 [0.91, 1.25]
4 studies · 541 participants
Moderate

Progression‐free survival · patients with epithelial ovarian cancer

Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).

1 finding from 1 review

Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
RR 1.07 [0.75, 1.54]
1 study · 141 participants
Low

3‐year OS · patients with epithelial ovarian cancer

Platin‐based maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).

1 finding from 1 review

Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
RR 1.06 [0.94, 1.18]
3 studies · 341 participants
Moderate

Progression‐free survival · patients with epithelial ovarian cancer

Platin‐based maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).

1 finding from 1 review

Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
RR 1.04 [0.86, 1.24]
3 studies · 341 participants
Moderate

3‐year OS · patients with epithelial ovarian cancer

Doxorubicin‐based maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).

1 finding from 1 review

Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
RR 1 [0.86, 1.15]
2 studies · 204 participants
Moderate